← All trials
NCT05278988
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 1, 2021
- Primary completion
- Sep 30, 2024
- Completion date
- Sep 30, 2024
- First posted
- Mar 15, 2022
- Last posted
- Aug 8, 2022
- Enrollment
- 60
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Huazhong University of Science and TechnologyLead sponsor
- Anhui Medical UniversityCollaborator
- Fudan UniversityCollaborator
- Jiao Tong UniversityCollaborator
- Fudan UniversityCollaborator
- Huazhong University of Science and TechnologyOverall official - principal investigator
- Huazhong University of Science and TechnologyReponsible party - principal investigator
- Weifang People's HospitalCollaborator
- Zhengzhou UniversityCollaborator
- Huazhong University of Science and TechnologyOfficial
- Huazhong University of Science and TechnologySponsor investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.